Navigation Links
BioMarin Announces Third Quarter 2009 Financial Results
Date:10/28/2009

verages our EU commercial infrastructure, fits our orphan drug strategy with a specialist oriented and potentially high priced therapeutic and has the potential for near-term value creation."

Net Product Revenue

Net product revenue from Naglazyme (galsulfase), an enzyme replacement therapy for mucopolysaccharidosis VI (MPS VI), was $42.1 million for the third quarter of 2009, an increase of 26.0 percent compared to Naglazyme net product revenue of $33.3 million for the third quarter of 2008. Net product revenue from Naglazyme for the nine months ended September 30, 2009 was $124.3 million, an increase of 29.2 percent from net product revenue of $96.2 million for the nine months ended September 30, 2008. Changes in foreign currency rates, net of hedges caused a negative impact to Naglazyme sales of $1.3 million and $5.0 million in the three and nine months ended September 30, 2009, respectively.

Net sales of Aldurazyme (laronidase), an enzyme replacement therapy for mucopolysaccharidosis I (MPS I) recorded by Genzyme, were $40.3 million for the third quarter of 2009, an increase of 5.5 percent compared to net sales of Aldurazyme by Genzyme of $38.2 million for the third quarter of 2008. Net sales of Aldurazyme recorded by Genzyme for the nine months ended September 30, 2009 were $116.4 million, compared to $113.7 million for the nine months ended September 30, 2008. Changes in foreign currency rates caused a negative impact to Aldurazyme sales by Genzyme of $1.5 million and $8.7 million in the three and nine months ended September 30, 2009, respectively. In the third quarter of 2009, Aldurazyme unit volume increased 11.6 percent compared to the third quarter of 2008 as the number of patients on therapy worldwide continues to grow.

Net product revenue to BioMarin related to Aldurazyme was $14.6 million for the third quarter of 2009, compared to net product revenue to BioMarin of $20.7 million for the third quar
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. BioMarin to Present at the Oppenheimer Healthcare Conference
2. BioMarin Acquires Huxley Pharmaceuticals, Inc.
3. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
4. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
5. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
6. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
7. BioMarin Announces FDA Approval for Kuvan
8. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
9. Rigel Announces Presentations at Two Investor Conferences
10. Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
11. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... and BOSTON , May 24, 2013 ... company, is pleased to announce that it has engaged Mr ... Company,s business development capabilities in Japan and ... years of experience in business development, licensing and alliance management in ... Pharma ( Japan ), Nippon Roche and Tanabe Seiyaku ...
(Date:5/23/2013)... PARÍS, 24 de mayo de 2013  Volcano ... desarrollador y fabricante de herramientas de precisión para ... tratamiento de la enfermedad vascular periférica y coronaria, ... ( Ad enosine V asodilator I ... durante la sesión de ensayo clínico hot line ...
(Date:5/23/2013)... , May 23, 2013  Haemonetics Corporation (NYSE: ... , CFO & EVP-Business Development, will present at The Deutsche ... Boston, MA on May 29, 2013 ... ) The public may access Mr. Lindop,s ... About Haemonetics Haemonetics (NYSE: HAE ...
Breaking Medicine Technology:Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
(Date:5/24/2013)... FRIDAY, May 24 (HealthDay News) -- Patients hospitalized for ... if they,re admitted on Mondays or in the morning, ... of stay are highest among heart failure patients admitted ... researchers, who are scheduled to present their findings Saturday ... Failure Association of the European Society of Cardiology. ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 The Mirena ... by recent news that the FDA has received more than ... side effects from the intrauterine birth control device known as ... more complicated issues reported by the women “included ‘expulsion,’ where ... reports of that occurring,” according to an ABC News article. ...
(Date:5/24/2013)... FRIDAY, May 24 (HealthDay News) -- Drugs commonly used ... side effects that can interfere with vision, according to ... analogues (PGAs), which are used to reduce eye pressure, ... and changes in eye color, the researchers said, suggesting ... for PGAs. Doctors should be conservative when ...
(Date:5/24/2013)... Amirsys today announces the release of ... instructors and students. Instructors can use the new features ... plan templates, targeted reading assignments, and customized instructions. For ... questions, 5,000 searchable anatomy glossary terms, and easier ways ... is the first gross anatomy resource to provide ...
(Date:5/24/2013)... BestSatelliteProviders.com the online satellite TV ... consumers compare the features and services offered by ... released the rankings of the best rural ... viewing on their website. , BestSatelliteProviders.com ... Adam Matthews, the spokesperson for BestSatelliteProviders.com, “When consumers ...
Breaking Medicine News(10 mins):Health News:Monday Best Time for Hospitalization With Heart Failure, Study Says 2Health News:Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes 2Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Amirsys AnatomyOne 2.0 Delivers Personalized Learning Plans 2Health News:Best Rural Internet Service Provider in 2013 by BestSatelliteProviders.com 2
... following is a,memorandum to editorial writers and columnists:, ... Communications,Director, SUBJECT: Katrina Storm Warning, On ... New Orleans,and the Gulf Coast are struggling to ... disasters in U.S. history. Disaster often strikes suddenly,and ...
... A new study released on,Monday, August 27, 2007 ... Prevention of Work-Related Musculoskeletal Disorders, held in,Boston, highlights ... both. Dr. Susan Buchanan, University of Illinois at,Chicago ... that raise,many questions as to why certain workers ...
... culprits behind the increase, , , THURSDAY, Aug. 30 (HealthDay ... sport early -- playing year-round, joining competitive club or ... believing they,ll put themselves on the fast track to ... , But for too many of these kids, that ...
... researchers say more study is needed to prove a link ... in damp, moldy homes may be prone to depression, a ... an analysis of mold and health conditions in several cities ... lead to the addition of emotional problems to the list ...
... The Mutter Museum will be taking its two Presidential ... the Arden Theater,s ASSASSINS on September 19., PHILADELPHIA, ... Arden Theater will display the actual remains of two,of ... opening,night of the Arden,s production of Assassins, Wednesday, September ...
... Calif., Aug. 30 Omnicell, Inc.,(Nasdaq: OMCL ) ... safety and operational efficiency in healthcare,facilities, today announced that ... vice president & CFO will present at the Thomas ... Boston, Mass.,on Wednesday, September 5, 2007 at 11:30 a.m. ...
Cached Medicine News:Health News:Campaign for America's Future Memorandum: Katrina Storm Warning 2Health News:Campaign for America's Future Memorandum: Katrina Storm Warning 3Health News:Campaign for America's Future Memorandum: Katrina Storm Warning 4Health News:Campaign for America's Future Memorandum: Katrina Storm Warning 5Health News:New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites 2Health News:New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites 3Health News:More Kids Are Suffering Sports Injuries 2Health News:More Kids Are Suffering Sports Injuries 3Health News:Damp, Moldy Homes May Cause Depression 2Health News:Damp, Moldy Homes May Cause Depression 3Health News:Damp, Moldy Homes May Cause Depression 4Health News:The Mutter Assassins Go to the Theater! 2Health News:The Mutter Assassins Go to the Theater! 3Health News:Omnicell to Present at Thomas Weisel Healthcare Conference 2007 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: